Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.16), $0.04 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $42.5 million versus the consensus estimate of $29.65 million.

GUIDANCE:

Halozyme Therapeutics sees FY2016 revenue of $130-145 million, versus the consensus of $127.89 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.